5-year survival outcomes with durvalumab after chemoradiotherapy in unresectable Stage III NSCLC - An update from the PACIFIC trial Meeting Abstract
| Authors: | de Wit, M.; Spigel, D. R.; Faivre-Finn, C.; Gray, J. E.; Vicente, D.; Planchard, D.; Paz-Ares, L.; Vansteenkiste, J. F.; Garassino, M. C.; Hui, R.; Quantin, X.; Rimner, A.; Wu, Y. L.; Özgüroğlu, M.; Lee, K. H.; Kato, T.; Macpherson, E.; Newton, M.; Thiyagarajah, P.; Antonia, S. J.; Reck, M. |
| Abstract Title: | 5-year survival outcomes with durvalumab after chemoradiotherapy in unresectable Stage III NSCLC - An update from the PACIFIC trial |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie (Hybrid-Kongress) |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 44 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2021 Oct 01-04 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2021-09-01 |
| Start Page: | 109 |
| End Page: | 110 |
| Language: | English |
| ACCESSION: | WOS:000760622600194 |
| PROVIDER: | wos |
| DOI: | 10.1159/000518417 |
| Notes: | Meeting Abstract: V142 -- Meeting was also presented virtually -- "Joint Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology (Hybrid Congress)" -- Source: Wos |
